Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (449) Arrow Down
Filter Results: (449) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (639)
    • People  (2)
    • News  (57)
    • Research  (449)
    • Events  (2)
    • Multimedia  (8)
  • Faculty Publications  (395)

Show Results For

  • All HBS Web  (639)
    • People  (2)
    • News  (57)
    • Research  (449)
    • Events  (2)
    • Multimedia  (8)
  • Faculty Publications  (395)
← Page 5 of 449 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • August 2001
  • Case

Scios, Inc.

By: Regina E. Herzlinger
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States
Citation
Educators
Related
Herzlinger, Regina E. "Scios, Inc." Harvard Business School Case 302-034, August 2001.
  • November 1991 (Revised April 1994)
  • Case

Nucleon, Inc.

By: Gary P. Pisano
Nucleon is a small biotechnology company whose first potential product is about to enter clinical testing. Before Nucleon can begin clinical trials, however, its management must decide how and where to manufacture the product. Three options are being contemplated: 1)... View Details
Keywords: Factories, Labs, and Plants; Entrepreneurship; Health Testing and Trials; Rights; Product Development; Production; Partners and Partnerships; Research and Development; Biotechnology Industry
Citation
Educators
Purchase
Related
Pisano, Gary P. "Nucleon, Inc." Harvard Business School Case 692-041, November 1991. (Revised April 1994.)
  • June 2011 (Revised October 2013)
  • Case

Gene Patents (A)

By: Richard Hamermesh, David Kiron and Phillip Andrews
In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues... View Details
Keywords: Courts and Trials; Patents; Genetics; Judgments; Science-Based Business; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Hamermesh, Richard, David Kiron, and Phillip Andrews. "Gene Patents (A)." Harvard Business School Case 811-089, June 2011. (Revised October 2013.)
  • Research Summary

Research Interests

Research interests are focused on issues of innovation and productivity as they relate to improved outcomes in biotechnology and pharmaceutical R and D. These span topics from decision-making, organizational structure and communication, to the development of novel... View Details

  • October 2001 (Revised April 2002)
  • Case

Calgene, Inc.

By: Ray A. Goldberg and John T. Gourville
In 1993, Calgene is on the verge of introducing the world's first genetically engineered plant product--a tomato will taste better and stay fresh longer. At the same time, it is using biotechnology to produce improved plant products for the cottonseed and the... View Details
Keywords: Information Technology; Marketing Strategy; Market Entry and Exit; Product Launch; Innovation Strategy; Social Issues; Production; Problems and Challenges; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Goldberg, Ray A., and John T. Gourville. "Calgene, Inc." Harvard Business School Case 502-041, October 2001. (Revised April 2002.)
  • August 2009 (Revised April 2012)
  • Case

Genzyme's CSR Dilemma: How to Play its HAND

By: Christopher A. Bartlett, Tarun Khanna and Prithwiraj Choudhury
Genzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should... View Details
Keywords: Global Strategy; Health Care and Treatment; Intellectual Property; Corporate Social Responsibility and Impact; Partners and Partnerships; Research and Development; Biotechnology Industry
Citation
Educators
Purchase
Related
Bartlett, Christopher A., Tarun Khanna, and Prithwiraj Choudhury. "Genzyme's CSR Dilemma: How to Play its HAND." Harvard Business School Case 910-407, August 2009. (Revised April 2012.)
  • December 2012
  • Teaching Note

Gene Patents (A) (TN)

By: Richard G. Hamermesh and Matthew Preble
This is the teaching note for case Gene Patents (A). In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our... View Details
Keywords: Biotech; Human Genome; Patents; Genetics; Biotechnology Industry; United States
Citation
Purchase
Related
Hamermesh, Richard G., and Matthew Preble. "Gene Patents (A) (TN)." Harvard Business School Teaching Note 813-099, December 2012.
  • October 2012 (Revised March 2022)
  • Case

Kleiner-Perkins and Genentech: When Venture Capital Met Science

By: Felda Hardymon and Tom Nicholas
Genentech is a rare success story in the biotechnology industry. Hundreds of billions of dollars of venture capital have been invested without the expected transformational effects. Established in 1976, Genentech was to develop the new science of recombinant DNA into... View Details
Keywords: Innovation & Entrepreneurship; Venture Capital; Innovation and Invention; Entrepreneurship; Information Technology; Science; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Hardymon, Felda, and Tom Nicholas. "Kleiner-Perkins and Genentech: When Venture Capital Met Science." Harvard Business School Case 813-102, October 2012. (Revised March 2022.)
  • December 2009 (Revised February 2012)
  • Case

Monsanto: Helping Farmers Feed the World

By: David E. Bell, Carin-Isabel Knoop and Mary Shelman
Monsanto has led the effort to bring biotechnology to bear on food production. Through some management missteps and consumer resistance the company had difficulties in its early years. But since Hugh Grant became CEO the picture has brightened with widespread adoption... View Details
Keywords: Food; Global Strategy; Leadership; Production; Agriculture and Agribusiness Industry; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Bell, David E., Carin-Isabel Knoop, and Mary Shelman. "Monsanto: Helping Farmers Feed the World." Harvard Business School Case 510-025, December 2009. (Revised February 2012.)
  • June 2018
  • Teaching Note

Sandra Brown Goes Digital

By: Rosabeth Moss Kanter and Jonathan Cohen
As a middle manager at a biotechnology company, Sandra Brown harnessed digital tools and social media to engage others and build campaigns for change in the company. This Teaching Note presents strategies for teaching the Sandra Brown case series, which follows Brown's... View Details
Keywords: Change Leadership; Change Management; Digital; Engagement; Stakeholder Engagement; Grassroots Movement; Health Care Industry; Career Path; Innovation; Leading Change; Management; Innovation and Management; Personal Development and Career; Organizational Change and Adaptation; Quality
Citation
Purchase
Related
Kanter, Rosabeth Moss, and Jonathan Cohen. "Sandra Brown Goes Digital." Harvard Business School Teaching Note 318-156, June 2018.
  • October 2016 (Revised September 2017)
  • Case

The CRISPR-Cas9 Quarrel

By: Richard G. Hamermesh and Matthew G. Preble
In mid-2016, the Broad Institute and the University of California, Berkeley were in the middle of a contentious patent dispute over which entity controlled a breakthrough gene editing technology called CRISPR-Cas9. With CRISPR-Cas9, scientists might soon be able to... View Details
Keywords: CRISPR; Broad Institute; University Of California Berkeley; Intellectual Property; Patents; Law; Lawsuits and Litigation; Science; Genetics; Entrepreneurship; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Hamermesh, Richard G., and Matthew G. Preble. "The CRISPR-Cas9 Quarrel." Harvard Business School Case 817-020, October 2016. (Revised September 2017.)
  • April 1993 (Revised May 1994)
  • Case

Genzyme Corporation: Strategic Challenges with Ceredase

Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has... View Details
Keywords: Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Biotechnology Industry; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Teisberg, Elizabeth O., and Sharon L. Rossi. "Genzyme Corporation: Strategic Challenges with Ceredase." Harvard Business School Case 793-120, April 1993. (Revised May 1994.)
  • January 1996
  • Case

Biogen, Inc.: rBeta Interferon Manufacturing Process Development

By: Steven C. Wheelwright
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing... View Details
Keywords: Learning; Technological Innovation; Management Analysis, Tools, and Techniques; Product Development; Organizational Change and Adaptation; Projects; Research and Development; Corporate Strategy; Biotechnology Industry
Citation
Educators
Purchase
Related
Wheelwright, Steven C. "Biogen, Inc.: rBeta Interferon Manufacturing Process Development." Harvard Business School Case 696-083, January 1996.
  • 2006
  • Book

Science Business: The Promise, the Reality, and the Future of Biotech

By: Gary P. Pisano
Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details
Keywords: Science; Business Ventures; Biotechnology Industry
Citation
Find at Harvard
Purchase
Related
Pisano, Gary P. Science Business: The Promise, the Reality, and the Future of Biotech. Boston: Harvard Business School Press, 2006.
  • November 2018
  • Case

David Hysong and SHEPHERD Therapeutics

By: Ananth Raman, John Masko and Aldo Sesia
In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his... View Details
Keywords: Cancer; Therapeutics; Drugs; Health Care and Treatment; Business Startups; Product Development; Financing and Loans; Growth and Development Strategy; Problems and Challenges
Citation
Educators
Related
Raman, Ananth, John Masko, and Aldo Sesia. "David Hysong and SHEPHERD Therapeutics." Harvard Business School Case 619-012, November 2018.
  • February 2000 (Revised October 2000)
  • Case

Kendle International Inc.

By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs
Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details
Keywords: Acquisition; Financing and Loans; Venture Capital; Stock Options; Banks and Banking; Debt Securities; International Finance; Financial Strategy; Management Skills; Private Ownership; Initial Public Offering; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Crane, Dwight B., Paul W. Marshall, and Indra Reinbergs. "Kendle International Inc." Harvard Business School Case 200-033, February 2000. (Revised October 2000.)
  • Research Summary

Does the Adoption of Rolling Forecasts Improve Planning?

This field study investigates the consequences of adopting rolling forecasts on organizational planning. Using quarterly product-line forecasted and realized sales data from several business units of a multinational biotechnology supplier, I find that subsequent to the... View Details
  • November 2008 (Revised July 2009)
  • Background Note

A Managerial Perspective on Clinical Trials

By: Arthur A. Daemmrich
This note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Safety; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Daemmrich, Arthur A. "A Managerial Perspective on Clinical Trials." Harvard Business School Background Note 709-033, November 2008. (Revised July 2009.)
  • April 1993 (Revised October 1995)
  • Case

ALZA and Bio-Electro Systems (A): Technological and Financial Innovation

By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details
Keywords: Risk and Uncertainty; Technological Innovation; Business Subsidiaries; Decision Choices and Conditions; Corporate Finance; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (A): Technological and Financial Innovation." Harvard Business School Case 293-124, April 1993. (Revised October 1995.)
  • January 2011 (Revised January 2012)
  • Supplement

The Case of the Unidentified Healthcare Companies2010 (CW)

By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
Keywords: Financial Statements; Financial Management; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry
Citation
Purchase
Related
Bohmer, Richard M.J., Ethan S. Bernstein, Margarita Krivitski, and Srinidhi Reddy. "The Case of the Unidentified Healthcare Companies2010 (CW)." Harvard Business School Spreadsheet Supplement 611-701, January 2011. (Revised January 2012.)
  • ←
  • 5
  • 6
  • …
  • 22
  • 23
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.